Imatinib as a paradigm of targeted therapies

被引：275

作者：

Druker, BJ ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Inst Canc, Portland, OR 97239 USA

来源：

ADVANCES IN CANCER RESEARCH, VOL 91 | 2004年 / 91卷

关键词：

D O I：

10.1016/S0065-230X(04)91001-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Imatinib (Gleevec) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer This article reviews the identification of the BCR-ABL tyrosine kinase as a therapeutic target in chronic myeloid leukemia and the steps in the development of an agent to specifically inactivate this abnormality. The clinical trials results are reviewed along with a description of resistance mechanisms. As imatinib also inhibits the tyrosine kinase activity of KIT and the platelet-derived growth factor receptors, the extension of imatinib to malignancies driven by these kinases will be described. Issues related to clinical trials of molecularly targeted agents are discussed, including patient and dose selection. Last, the translation of this paradigm to other malignancies is explored. (C) 2004 Elsevier Inc.

引用

页码：1 / +

页数：32

共 103 条

[1]

ABELSON HT, 1970, CANCER RES, V30, P2213

[2] High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib [J].

Al-Ali, HK ;

Heinrich, MC ;

Lange, T ;

Krahl, R ;

Mueller, M ;

Müller, C ;

Niederwieser, D ;

Druker, BJ ;

Deininger, MWN .

HEMATOLOGY JOURNAL, 2004, 5 (01) :55-60

[3] Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].

Apperley, JF ;

Gardembas, M ;

Melo, JV ;

Russell-Jones, R ;

Bain, BJ ;

Baxter, J ;

Chase, A ;

Chessells, JM ;

Colombat, M ;

Dearden, CE ;

Dimitrijevic, S ;

Mahon, FX ;

Marin, D ;

Nikolova, Z ;

Olavarria, E ;

Silberman, S ;

Schultheis, B ;

Cross, NCP ;

Goldman, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487

[4] Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 [J].

Barthe, C ;

Gharbi, MJ ;

Lagarde, V ;

Chollet, C ;

Cony-Makhoul, P ;

Reiffers, J ;

Goldman, JM ;

Melo, JV ;

Mahon, FX .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) :109-111

[5] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[6]

Bennett JH., 1845, EDINBURGH MED SURG J, P413

[7]

Beran M, 1998, CLIN CANCER RES, V4, P1661

[8] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[9] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[10]

Buchdunger E, 1996, CANCER RES, V56, P100

← 1 2 3 4 5 6 7 8 9 10 →